Profile data is unavailable for this security.
About the company
Labcorp Holdings Inc. provides comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. By leveraging its unparalleled diagnostics and drug development capabilities, the Company provides insights and accelerates innovations to improve health and improve lives. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The Company serves clients in more than 100 countries.
- Revenue in USD (TTM)12.30bn
- Net income in USD399.20m
- Incorporated2024
- Employees67.00k
- LocationLabcorp Holdings Inc358 S Main StBURLINGTON 27215United StatesUSA
- Phone+1 (336) 229-1127
- Fax+1 (302) 636-5454
- Websitehttps://www.labcorp.com/
Mergers & acquisitions
| Acquired company | LH:NYQ since announced | Transaction value |
|---|---|---|
| Baystate Health Inc-Outreach Laboratory business | -2.77% | -- |
| Tufts Medicine-Outreach Laboratory Business | -9.32% | -- |
| Legacy Health System-Outreach Laboratory Select Assets | -7.40% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chemed Corp | 2.29bn | 283.41m | 8.39bn | 15.09k | 29.84 | 7.07 | 24.31 | 3.66 | 18.58 | 18.58 | 150.33 | 78.46 | 1.45 | 138.48 | 13.85 | 152,017.80 | 17.94 | 19.53 | 21.86 | 24.64 | 35.47 | 34.60 | 12.36 | 12.60 | 1.88 | -- | 0.0114 | 8.15 | 6.06 | 4.90 | 9.17 | 5.80 | 1.46 | 6.10 |
| Encompass Health Corp | 4.96bn | 386.50m | 8.70bn | 22.36k | 22.73 | 4.99 | 11.14 | 1.75 | 3.80 | 3.68 | 48.76 | 17.30 | 0.8276 | -- | 8.74 | 221,721.20 | 8.36 | 6.37 | 10.58 | 7.94 | 95.50 | 95.58 | 10.10 | 9.16 | -- | 5.59 | 0.5298 | 30.78 | 10.41 | 2.34 | 41.31 | 4.49 | 16.60 | -10.42 |
| Solventum Corp | 8.20bn | 1.29bn | 10.25bn | 22.01k | 7.93 | 2.66 | 5.55 | 1.25 | 7.48 | 7.48 | 47.54 | 22.30 | -- | -- | -- | 372,699.60 | -- | -- | -- | -- | 57.64 | -- | 15.73 | -- | 1.33 | 43.79 | 0.6832 | -- | 0.8241 | -- | 0.2234 | -- | -- | -- |
| Universal Health Services, Inc. | 14.66bn | 816.29m | 12.58bn | 73.35k | 16.09 | 2.03 | 9.05 | 0.8579 | 11.79 | 11.79 | 211.29 | 93.48 | 1.06 | -- | 6.77 | 199,837.00 | 5.96 | 6.44 | 6.98 | 7.63 | -- | -- | 5.61 | 6.55 | 1.28 | 6.16 | 0.4352 | 6.06 | 6.59 | 5.80 | 6.32 | -1.47 | 1.17 | 14.87 |
| Davita Inc | 12.34bn | 815.64m | 12.90bn | 70.00k | 16.71 | 13.93 | 6.99 | 1.05 | 8.81 | 8.81 | 133.10 | 10.56 | 0.7224 | 66.04 | 5.30 | 176,257.20 | 6.40 | 5.62 | 8.50 | 7.45 | 32.40 | 30.70 | 8.85 | 8.33 | 1.37 | 5.01 | 0.7759 | -- | 4.57 | 1.26 | 26.44 | 2.33 | -10.47 | -- |
| Tenet Healthcare Corp | 20.90bn | 2.62bn | 13.21bn | 78.14k | 5.23 | 3.82 | 3.14 | 0.6322 | 25.87 | 25.87 | 201.91 | 35.35 | 0.7466 | 9.04 | 6.50 | 267,391.00 | 11.97 | 3.61 | 17.38 | 5.09 | 82.64 | 82.97 | 16.03 | 4.95 | 1.37 | 4.49 | 0.6267 | 0.00 | 7.17 | 2.33 | 49.02 | 41.42 | 4.01 | -- |
| Quest Diagnostics Inc | 9.29bn | 842.00m | 15.77bn | 40.00k | 19.10 | 2.45 | 11.97 | 1.70 | 7.43 | 7.43 | 82.00 | 57.95 | 0.6944 | 33.57 | 7.21 | 232,175.00 | 6.51 | 9.28 | 7.61 | 10.81 | 32.95 | 36.64 | 9.37 | 12.97 | 0.8908 | 8.40 | 0.4184 | 25.07 | -6.38 | 4.20 | -9.77 | 3.40 | 1.27 | 7.43 |
| Labcorp Holdings Inc | 12.30bn | 399.20m | 16.43bn | 67.00k | 42.67 | 2.06 | 17.00 | 1.34 | 4.57 | 4.95 | 142.45 | 94.42 | 0.6698 | 18.59 | 4.68 | 183,588.10 | 2.18 | 6.27 | 2.68 | 7.37 | 27.74 | 32.33 | 3.25 | 9.51 | 0.7564 | 5.95 | 0.3934 | -- | 2.51 | 1.42 | -62.16 | -16.40 | 3.62 | -- |
| Molina Healthcare Inc | 35.85bn | 1.07bn | 18.43bn | 18.00k | 17.06 | 4.13 | 14.83 | 0.5142 | 18.43 | 18.43 | 617.11 | 76.15 | 2.48 | -- | 12.18 | 1,991,889.00 | 7.42 | 7.62 | 16.79 | 16.80 | 15.74 | 15.99 | 2.99 | 3.04 | -- | 14.69 | 0.3465 | 0.00 | 6.56 | 12.52 | 37.75 | 9.06 | 22.87 | -- |
| Holder | Shares | % Held |
|---|---|---|
| UBS Fund Management (Luxembourg) SAas of 23 May 2024 | 772.00 | 0.00% |
| abrdn Alternative Investments Ltd.as of 24 May 2024 | 110.00 | 0.00% |
